EXOZ · ISSUER CIK 2010788
EXOZYMES INC.
Between Aug 1, 2026 and Oct 29, 2026, 3 EXOZYMES INC. insiders reported $6K of open-market purchases and $19K of sales on SEC Form 4. The largest buyer was Heltzen Michael (Chief Executive Officer), with $6K.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 1 sales were reported under a 10b5-1 plan.
$6KInsider buying
$19KInsider selling
−$13KNet open-market
Oct 26, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 202615:01 | Oct 12, 2026 | EXOZ | Chief Commercial Officer | S · SellLate 14d | $5.21 | −3,729 | 28,692 | -12% | −$19K | ||
| Oct 26, 202615:01 | Oct 9, 2026 | EXOZ | Chief Commercial Officer | M · ExerciseLate 17d | — | +3,922 | 32,421 | +14% | — | ||
| Sep 2, 202619:33 | Aug 26, 2026from Aug 25, 2026 | EXOZ | Chief Executive Officer | P · BuyLate 7d | $7.49 | +855 | 13,953 | +7% | +$6K | -24.4% | -45.1% |
| Sep 2, 202619:33 | Aug 19, 2026 | EXOZ | Chief Executive Officer | A · GrantLate 14d | $6.40 | +8,841 | 13,853 | +176% | $57K | ||
| Aug 25, 202619:16 | Aug 19, 2026 | EXOZ | Chief Commercial Officer | M · ExerciseLate 6d | — | +19,612 | 28,499 | +221% | — | ||
| Aug 25, 202618:57 | Aug 19, 2026 | EXOZ | Chief Scientific Officer | M · ExerciseLate 6d | — | +32,964 | 762,837 | +5% | — |